And Tewk, with those sort of numbers you'd have to think someone would swallow up ACL at some stage if the Phase III results 'exceeds the efficacy of Erbitux in combination with FOLFIRI.' The numbers you've provided would be impossible for a large pharma to ignore, let alone the other potential Hyact applications. Do you think a Nasdaq listing would benefit/be possible, prior to any potential takeover?
- Forums
- ASX - By Stock
- TSN
- Puma and ACL
Puma and ACL, page-2
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online